Recent Updates
Recently added Catalysts
AURA Positive Sentiment

Aura Biosciences to Participate in Upcoming May 2026 Investor Conferences

Key Takeaway: Aura Biosciences, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences. The senior management team will engage in fireside chats, which will be available for live streaming and later archived. The company is dedicated to developing therapies for solid tumors, with its lead candidate in late-stage development.
Price reaction · baseline $7.93 (2026-05-12 close) · hit pre-market · clean, no other AURA news in the window
day 0 close · peak
+1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Aura Biosciences is participating in multiple investor conferences.
  • The company is focused on developing innovative therapies for solid tumors.
  • Aura's lead candidate is in late-stage development for choroidal melanoma.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+4%
120-day peak, hindsight
Typical move
7%
average across 5 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
Bel-sar
Phase 3 · Choroidal Melanoma

Full Press Release Details

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) --Aura Biosciences, Inc.(NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:
Fireside Chat at 12:00 p.m. ET
Fireside Chat at 1:30 p.m. ET
The live webcasts of the fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website athttps://ir.aurabiosciences.com/events-and-presentations, where a replay of each webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Aura’s lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura is headquartered in Boston, MA. Aura’s mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
For more information, visitaurabiosciences.com. Follow us on X, @AuraBiosciences, and visit us on LinkedIn.

Investor and Media Relations Contact:

Alex Dasalla

Frequently Asked Questions

What is the focus of Aura Biosciences?

Aura Biosciences develops precision therapies for solid tumors.

When will Aura participate in investor conferences?

Aura will participate in investor conferences in May 2026.

Where can I watch the investor conference webcasts?

The webcasts will be available on Aura's 'Investors & Media' page.

What is Aura's lead candidate?

Aura's lead candidate is bel-sar (AU-011) for choroidal melanoma.

Last updated: May 13, 2026